128 related articles for article (PubMed ID: 38416410)
1. Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II.
Hanna GJ; Grover P; Elliott A; McGrath J; Xiu J; Sukari A; Johnson JM; Wise-Draper T
Clin Cancer Res; 2024 May; 30(10):2225-2232. PubMed ID: 38416410
[TBL] [Abstract][Full Text] [Related]
2. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R; Mitani Y; Diao L; Guijarro I; Wang J; Zweidler-McKay P; Bell D; William WN; Glisson BS; Wick MJ; Kapoun AM; Patnaik A; Eckhardt G; Munster P; Faoro L; Dupont J; Lee JJ; Futreal A; El-Naggar AK; Heymach JV
J Clin Oncol; 2017 Jan; 35(3):352-360. PubMed ID: 27870570
[TBL] [Abstract][Full Text] [Related]
3. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets.
Ferrarotto R; Mitani Y; McGrail DJ; Li K; Karpinets TV; Bell D; Frank SJ; Song X; Kupferman ME; Liu B; Lee JJ; Glisson BS; Zhang J; Aster JC; Lin SY; Futreal PA; Heymach JV; El-Naggar AK
Clin Cancer Res; 2021 Feb; 27(3):852-864. PubMed ID: 33172898
[TBL] [Abstract][Full Text] [Related]
4. The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication.
Dou S; Li R; He N; Zhang M; Jiang W; Ye L; Yang Y; Zhao G; Yang Y; Li J; Chen D; Zhu G
Front Immunol; 2021; 12():618367. PubMed ID: 34552580
[TBL] [Abstract][Full Text] [Related]
5. Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes.
Sridharan V; Gjini E; Liao X; Chau NG; Haddad RI; Severgnini M; Hammerman P; El-Naggar A; Freeman GJ; Hodi FS; Rodig SJ; Dranoff G; Schoenfeld JD
Cancer Immunol Res; 2016 Aug; 4(8):679-87. PubMed ID: 27312343
[TBL] [Abstract][Full Text] [Related]
6. Diffuse Staining for Activated NOTCH1 Correlates With NOTCH1 Mutation Status and Is Associated With Worse Outcome in Adenoid Cystic Carcinoma.
Sajed DP; Faquin WC; Carey C; Severson EA; H Afrogheh A; A Johnson C; Blacklow SC; Chau NG; Lin DT; Krane JF; Jo VY; Garcia JJ; Sholl LM; Aster JC
Am J Surg Pathol; 2017 Nov; 41(11):1473-1482. PubMed ID: 28914715
[TBL] [Abstract][Full Text] [Related]
7. Morphological heterogeneity of oral salivary gland carcinomas: a clinicopathologic study of 41 cases with long term follow-up emphasizing the overlapping spectrum of adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma.
Schwarz S; Müller M; Ettl T; Stockmann P; Zenk J; Agaimy A
Int J Clin Exp Pathol; 2011 Apr; 4(4):336-48. PubMed ID: 21577319
[TBL] [Abstract][Full Text] [Related]
8. Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands.
Mosconi C; de Arruda JAA; de Farias ACR; Oliveira GAQ; de Paula HM; Fonseca FP; Mesquita RA; Silva TA; Mendonça EF; Batista AC
Oral Oncol; 2019 Jan; 88():95-101. PubMed ID: 30616805
[TBL] [Abstract][Full Text] [Related]
9. MYB, MYBL1, MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma.
Fujii K; Murase T; Beppu S; Saida K; Takino H; Masaki A; Ijichi K; Kusafuka K; Iida Y; Onitsuka T; Yatabe Y; Hanai N; Hasegawa Y; Inagaki H
Histopathology; 2017 Nov; 71(5):823-834. PubMed ID: 28594149
[TBL] [Abstract][Full Text] [Related]
10. Association between high expression of phosphorylated Akt and mammalian target of rapamycin and improved survival in salivary gland adenoid cystic carcinoma.
Ouyang DQ; Liang LZ; Ke ZF; Zheng GS; Weng DS; Yang WF; Su YX; Liao GQ
Head Neck; 2017 Jun; 39(6):1145-1154. PubMed ID: 28230926
[TBL] [Abstract][Full Text] [Related]
11. MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma.
Rettig EM; Tan M; Ling S; Yonescu R; Bishop JA; Fakhry C; Ha PK
Laryngoscope; 2015 Sep; 125(9):E292-9. PubMed ID: 25963073
[TBL] [Abstract][Full Text] [Related]
12. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations.
Mitani Y; Liu B; Rao PH; Borra VJ; Zafereo M; Weber RS; Kies M; Lozano G; Futreal PA; Caulin C; El-Naggar AK
Clin Cancer Res; 2016 Feb; 22(3):725-33. PubMed ID: 26631609
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of 1p36 locus deletion in adenoid cystic carcinoma of the salivary glands.
Šteiner P; Andreasen S; Grossmann P; Hauer L; Vaněček T; Miesbauerová M; Santana T; Kiss K; Slouka D; Skálová A
Virchows Arch; 2018 Oct; 473(4):471-480. PubMed ID: 29619555
[TBL] [Abstract][Full Text] [Related]
14. Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments.
de Sousa LG; Jovanovic K; Ferrarotto R
Curr Treat Options Oncol; 2022 Aug; 23(8):1135-1150. PubMed ID: 35854180
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA dysregulation in adenoid cystic carcinoma of the salivary gland in relation to prognosis and gene fusion status: a cohort study.
Andreasen S; Tan Q; Agander TK; Hansen TVO; Steiner P; Bjørndal K; Høgdall E; Larsen SR; Erentaite D; Olsen CH; Ulhøi BP; Heegaard S; Wessel I; Homøe P
Virchows Arch; 2018 Sep; 473(3):329-340. PubMed ID: 30069755
[TBL] [Abstract][Full Text] [Related]
16. The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype.
Linxweiler M; Kuo F; Katabi N; Lee M; Nadeem Z; Dalin MG; Makarov V; Chowell D; Dogan S; Ganly I; Hakimi AA; Wong RJ; Riaz N; Ho AL; Chan TA; Morris LGT
Clin Cancer Res; 2020 Jun; 26(12):2859-2870. PubMed ID: 32060100
[TBL] [Abstract][Full Text] [Related]
17. Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland.
Bell D; Ferrarotto R; Fox MD; Roberts D; Hanna EY; Weber RS; El-Naggar AK
Cancer Biol Ther; 2015; 16(6):834-8. PubMed ID: 25923130
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of gefitinib in patients with advanced salivary gland cancers.
Jakob JA; Kies MS; Glisson BS; Kupferman ME; Liu DD; Lee JJ; El-Naggar AK; Gonzalez-Angulo AM; Blumenschein GR
Head Neck; 2015 May; 37(5):644-9. PubMed ID: 24585506
[TBL] [Abstract][Full Text] [Related]
20. In-depth characterization of the salivary adenoid cystic carcinoma transcriptome with emphasis on dominant cell type.
Bell D; Bell AH; Bondaruk J; Hanna EY; Weber RS
Cancer; 2016 May; 122(10):1513-22. PubMed ID: 26953815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
